Class 4

Class 4 Medicines Defect Notification: Azithromycin 250 mg Capsules, EL(25)A/11 (UPDATED)

Jubilant Pharmaceuticals NV has informed the MHRA that the Patient information leaflet (PIL) in the cartons for the batches listed in the table include an outdated PIL. These packs contain a PIL which was revised in October 2021. The latest approved PIL is dated February 2025.

DMRC Number: DMRC-34866680

Company name: Jubilant Pharmaceuticals NV

Product description: Azithromycin 250 mg Capsules Licence: PL 19156/0138, SNOMED code: 1303911000001105 (4 Cap/pack), 1135911000001109 (6 Cap/pack)

Details of the affected batches

Batch No.Expiry DatePack SizeFirst Distributed
ZQ122005A09.20254 Cap/pack07/11/2023
ZQ122006A09.20256 Cap/pack14/02/2023
ZQ122007A09.20256 Cap/pack11/08/2023
ZQ122008A09.20256 Cap/pack08/11/2023
ZQ123003B09.20256 Cap/pack26/01/2024
ZQ123004A09.20256 Cap/pack27/02/2024
ZQ124001A12.20266 Cap/pack28/02/2024
ZQ124002A12.20264 Cap/pack24/05/2024
ZQ124003A12.20264 Cap/pack22/07/2024
ZQ124005A07.20266 Cap/pack19/12/2024
ZQ124006A07.20274 Cap/pack07/01/2025

Brief description of problem:

Jubilant Pharmaceuticals NV has informed the MHRA that the Patient information leaflet (PIL) in the cartons for the batches listed in the table above include an outdated PIL. These packs contain a PIL which was approved prior to 2021 but should contain a PIL that was updated in October 2021. Subsequently, a new PIL has been approved in February 2025.

The out of date PIL in the tabled batches is missing important updated safety information, please refer to the table in Appendix 2 and a copy of the full PIL is also available on the MHRA website.

Advice to Healthcare Professionals:

Healthcare professionals are advised to review the information contained within this notification and take this into account when prescribing this product. When products from batches included in the table is supplied or dispensed, please ensure that patients are aware of the missing information which is summarised in the ‘Advice for Patients’ box below and provided in Appendix 2. As the patients would not find current PIL in the packs, please inform the patients that the latest PIL for Azithromycin Capsules is available on the MHRA website.

Advice to Patients:

Patients should continue to take medicines from the impacted batches as prescribed by your healthcare professional. This does not affect the quality of the product. There is updated safety information in the latest patient information leaflet (PIL) which accompanies the medicine. The latest PIL is available on the MHRA website. There is some missing information which is presented below:

What you need to know before you take  Azithromycin

Other medicines and Azithromycin

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines

  • Hydroxychloroquine or chloroquine (used to treat conditions including rheumatoid arthritis, or to treat or prevent malaria): Taking these medicines at the same time as azithromycin may increase the chance of you getting side effects that affect your heart.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Company contacts for further information:

For medical information enquiries please email safety.uk@lambda-cro.com or telephone 0080089013370

For stock control enquiries please email JPUK.Customerservice@jubl.com , or telephone 01233 552293

To access the full recall: Class 4 Medicines Defect Notification: Azithromycin 250 mg Capsules, EL(25)A/11